▶주메뉴 바로가기
▶본문 바로가기
[ THE INVESTOR ] Daewoong Pharmaceutical said on April 19 that its generic antibiotic Meropenem has hit shelves in the US. Meropenem, which is used in treatment for a wide range of diseases rang...
[ THE INVESTOR ] SONGDO, Incheon -- Korea’s Celltrion will take away half of Johnson & Johnson’s Remicade market in the US with its biosimilar drug that hit the country last year, the company’s ...
[ THE INVESTOR ] Inside the plants of Celltrion at Songdo, Incheon, on a recent visit, there was a constant buzz as machines ran on full capacity to churn out 1.4 million biosimilar injection uni...
[ THE INVESTOR ] US private equity firm Bain Capital’s plans to acquire botulinum toxin maker Hugel has rattled its Korean rivals who are seeking to get a foothold in the US market. Besides Hug...
[ THE INVESTOR ] Korean botulinum toxic maker Hugel is expected to look for a new sales partner before its planned entry into the lucrative US market possibly later next year. Currently, Austri...
[ THE INVESTOR ] Celltrion on April 18 said its Truxima, a biosimilar version of Roche’s blockbuster lymphatic cancer treatment Rituxan, has hit shelves in the UK. The company said Truxima is be...
[ THE INVESTOR ] Chinese biotech firm HitGen said on April 18 that the company has entered into a multi-year research collaboration and license agreement with Pfizer to build and screen novel DNA-...
[ THE INVESTOR ] Major pharmaceutical firms saw their revenues from exports of active pharmaceutical ingredients increase last year, industry sources said on April 18. Yuhan , a major drug compan...
[ THE INVESTOR ] US private equity firm Bain Capital will acquire Hugel for about 900 billion won (US$792 million) in its latest push to expand its health care portfolio, the Korean botulinum to...
[ THE INVESTOR ] Korea’s botulinum toxic product maker Medytox is looking to acquire promising skin care firms in order to create synergies with its flagship wrinkle smoother business. “The tar...
[ THE INVESTOR ] The fight has dragged on for the past year, but the chief executive of Medytox is determined to uphold his claim that rival Daewoong Pharmaceutical stole its key ingredient to ...
[ THE INVESTOR ] Eli Lilly and Boehringer Ingelheim launched Basaglar, a biosimilar referencing Sanofi’s blockbuster insulin drug Lantus, in South Korea on April 13, intent on challenging the origi...
[ THE INVESTOR ] Genexine said on April 13 that its long-acting diabetes drug candidate has got funding of 2.1 billion won (US$1.85 million) from the Korean government. The Ministry of Health an...
[ THE INVESTOR ] Celltrion has sought approval from Japan’s Health Ministry for its biosimilar drug Herzuma, with aims to start sales in 2018. the Korean biopharmaceutical firm said on April 13. ...
[ THE INVESTOR ]The 2017 Bio Korea International Convention opened at COEX in southern Seoul for a three-day run on April 12. More than 650 bio companies from both home and abroad showcased their ...
This week's DECODED X
Samsung's share in Chinese smartphone market falls to 3%
Celltrion’s earnings double on strong Remsima sales
SK hynix increases facility investment to W10tr
Hyundai Kona sales to exceed 10,000 units in July
Renault likely to produce Twizy in Korea
Samsung Bioepis heats up price war in Remicade biosimilar market
SK to invest W372b in Chinese logistics firm
